Bristol Myers Squibb stock trades near consensus target after solid 2026 earnings
Published on 09/14/2026 at 16:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US1078421011) closed at USD 63.52 on the New York Stock Exchange on September 11, 2026, representing a 0.35 percent decline on the day according to MarketBeat data.
Stock trades close to analyst target
According to MarketBeat on September 11, 2026, Bristol Myers Squibb shares closed at USD 63.52 on the New York Stock Exchange, with the portal citing a consensus analyst price target of USD 66.33 for the stock.
As MarketBeat reports on September 14, 2026, this translates into Bristol Myers Squibb stock trading about USD 2.81, or approximately 4.4 percent, below the consensus target, leaving room for potential upside if analysts' expectations are met.
Earnings show revenue and EPS growth
According to an overview of recent filings on Stock Titan, Bristol Myers Squibb reported second-quarter 2026 total revenue of USD 12,973 million, up 6 percent year over year as portfolio growth offset pressure in older products.
In the same second-quarter 2026 report, the Growth Portfolio generated USD 7,560 million, an increase of 15 percent compared with the prior-year quarter, while the Legacy Portfolio contributed USD 5,422 million, down 4 percent as generic competition weighed on established oncology therapies, according to Stock Titan.
The second-quarter 2026 figures also showed improvement in profitability: GAAP diluted earnings per share rose to USD 1.62 from USD 0.64 a year earlier, and non-GAAP diluted EPS increased to USD 2.04 from USD 1.46, indicating stronger underlying earnings power, as detailed by Stock Titan.
Within the product mix, Eliquis stood out with second-quarter 2026 revenue of USD 4,481 million, up 22 percent year over year, underlining the blood thinner's role as a key growth driver, according to Stock Titan.
Guidance underpins medium-term expectations
Looking ahead, Bristol Myers Squibb raised its 2026 non-GAAP total revenue outlook to a range of USD 49.0 billion to USD 50.0 billion and increased non-GAAP EPS guidance to USD 6.75 to USD 7.00, reflecting momentum in key therapies, as reported by Stock Titan in its summary of the second-quarter 2026 update.
The guidance assumes worldwide Eliquis revenue growth of around 20 to 25 percent and operating expenses of about USD 16.5 billion in 2026, indicating that management expects continued strength from the Growth Portfolio while keeping a tight rein on costs, according to Stock Titan.
Earlier in the year, Bristol Myers Squibb reported first-quarter 2026 total revenue of USD 11,489 million, up 3 percent from the same period in 2025, as demand in its Growth Portfolio and for Eliquis helped offset declines in older brands, according to Stock Titan.
In that first-quarter 2026 update, the Growth Portfolio generated USD 6.2 billion in revenue, rising 12 percent year over year, while the Legacy Portfolio declined to USD 5.3 billion, down 6 percent, showing a clear shift in the revenue mix toward newer therapies, as summarized by Stock Titan.
For investors, the quantified shift toward growth products and the raised 2026 guidance provide a concrete backdrop for the current valuation, with the share price only moderately below the consensus target, suggesting that earnings delivery will be closely watched.
Analyst view and valuation context
According to MarketBeat on September 14, 2026, Bristol Myers Squibb currently holds a consensus rating of Moderate Buy, and analysts collectively forecast non-GAAP diluted EPS around the upper end of the company’s 2026 guidance range.
The same overview notes that equities analysts expect Bristol Myers Squibb to post about USD 6.95 in EPS for the current fiscal year 2026, which sits within the company’s own non-GAAP guidance band of USD 6.75 to USD 7.00, indicating broad alignment between internal targets and external expectations, according to MarketBeat.
In that earnings context, MarketBeat highlights that Bristol Myers Squibb reported EPS of USD 2.04 for the second quarter of 2026, beating analysts' consensus estimates of USD 1.60 by USD 0.44 and delivering revenue of USD 12.97 billion against expectations of USD 11.74 billion, underscoring the degree to which the company exceeded forecasts, according to MarketBeat.
For valuation-focused investors, the combination of mid-single-digit to low-double-digit revenue growth, EPS expansion and a share price trading only a few dollars below the consensus target provides a quantified framework for assessing risk and reward in Bristol Myers Squibb stock.
Stock level and market metrics
Per data cited by MarketBeat, Bristol Myers Squibb stock closed at USD 63.52 on the New York Stock Exchange on September 11, 2026, with the site also noting extended trading indications of USD 64.37 on September 14, 2026, though the completed closing price of September 11, 2026 remains the firm benchmark.
At a closing level of USD 63.52 on September 11, 2026, and assuming a consensus price target of USD 66.33, Bristol Myers Squibb stock trades roughly 4.4 percent below that target, a gap that reflects both the earnings momentum and the residual risks tied to legacy product erosion and competitive dynamics in key therapeutic areas.
Bristol Myers Squibb stock - key data
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 11, 2026, 03:58 PM): 63.52 USD
- Market capitalization: 131,000,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
